Tci Wealth Advisors, Inc. Prothena Corp Public LTD CO Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$46.97 - $58.27 $1,690 - $2,097	-36 Reduced 13.69%	227 $11,000
Q4 2022 Feb 06, 2023	BUY	$52.05 - $65.0 $1,873 - $2,340	36 Added 15.86%	263 $15,000
Q3 2022 Nov 08, 2022	BUY	$25.16 - $60.63 $25 - $60	1 Added 0.44%	227 $14,000
Q2 2022 Jul 19, 2022	BUY	$22.73 - $39.98 $2,000 - $3,518	88 Added 63.77%	226 $6,000
Q1 2022 Apr 29, 2022	SELL	$30.27 - $49.22 $665 - $1,082	-22 Reduced 13.75%	138 $5,000
Q4 2021 Jan 24, 2022	BUY	$42.11 - $73.26 $1,810 - $3,150	43 Added 36.75%	160 $8,000
Q3 2021 Oct 29, 2021	BUY	$48.2 - $78.89 $1,108 - $1,814	23 Added 24.47%	117 $8,000
Q2 2021 Aug 02, 2021	BUY	$21.63 - $57.65 $2,033 - $5,419	94 New	94 $5,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $641M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.